Women who took up another COX-2(COX-2 switchers) were significantly more likely to have been a continuous rofecoxib user (47% compared to 14%, p < 0.0001), and to have a diagnosis of arthritis (86% compared to 77%, p = 0.003), than were COX-2 stoppers. The gene discussed is PTGS2; the disease is Arthritis.